Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD)

NCT01863199 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Neovascular Age Related Macular Degeneration

Interventions

DRUG: Lucentis (Treat and extend)
DRUG: Lucentis every 4 weeks
DRUG: Lucentis every 12 weeks

Sponsor

Retinal Consultants of Arizona

Collaborators

[object Object]